COMBINATION OF LONG-ACTING FUROSEMIDE AND INSTANT-ACTING AMILORIDE - PHARMACOKINETICS AND PHARMACODYNAMICS IN HUMAN-SUBJECTS

被引:9
作者
FLOUVAT, B
ROUX, A
LENEVEU, A
PRINSEAU, J
ALEXANDRE, JA
机构
[1] HOP AMBROISE PARE,SERV BIOCHIM LAB,F-92104 BOULOGNE BILLANCO,FRANCE
[2] HOP AMBROISE PARE,SERV MED INTERNE,F-92104 BOULOGNE BILLANCO,FRANCE
关键词
DIURETICS; AMILORIDE; FUROSEMIDE; PHARMACOKINETICS; PHARMACODYNAMICS;
D O I
10.1111/j.1472-8206.1991.tb00762.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics and pharmacodynamics of the combination of amiloride (2 x 2.5 mg) and long-acting furosemide (2 x 10 mg) were compared with amiloride (5 mg) and furosemide (20 mg) in 12 healthy male volunteers aged 26.2 +/- 1.6 years and weighing 68.8 +/- 6.2 kg, after random order administration. Furosemide and amiloride plasma or urine concentrations were determined by HPLC with fluorimetric detection. The rate of absorption (t(max) = 3 h) and the bioavailability of the two diuretics were not significantly modified by their combination. Furosemide plasma half-life was 2.77 +/- 1.04 h after the combination treatment and 2.76 +/- 0.98 h alone, amiloride plasma half-life was respectively 15.7 +/- 4.6 h and 14.6 +/- 3.7 h. The urinary elimination of furosemide was significantly higher in the 2-4 h interval in the combination treatment, accompanying its delayed maximum effect of diuresis. A synergistic effect was observed after the combination administration of the two diuretics; between the 2nd and the 8th hour, the sodium elimination was significantly increased (P < 0.01) and the potassium excretion was significantly decreased (P = 0.05). After a single dose, no modification of plasma or erythrocyte magnesium levels was observed. This study shows that the combination of the two drugs entails a synergy of their activities which does not involve pharmacokinetic changes.
引用
收藏
页码:741 / 752
页数:12
相关论文
共 18 条
[1]  
BABA WI, 1968, CLIN PHARMACOL THER, V9, P318
[2]  
BEERMANN B, 1982, CLIN PHARMACOL THER, V3, P584
[3]   PHARMACOKINETICS-PHARMACODYNAMICS OF FUROSEMIDE IN MAN - REVIEW [J].
BENET, LZ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1979, 7 (01) :1-27
[4]   CLINICAL PHARMACOKINETICS OF FRUSEMIDE [J].
CUTLER, RE ;
BLAIR, AD .
CLINICAL PHARMACOKINETICS, 1979, 4 (04) :279-296
[5]  
GRAYSON MF, 1971, BRIT J PHARMACOL, V43, P473
[6]   PHARMACODYNAMICS AND PHARMACOKINETICS OF FUROSEMIDE COMBINATIONS WITH POTASSIUM-RETAINING AND THIAZIDE-LIKE DIURETICS - CLEARANCE AND MICROPUNCTURE STUDIES [J].
HROPOT, M ;
SORGEL, F ;
MUTSCHLER, E .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1986, 333 (04) :457-461
[7]   SPECIMEN HANDLING AND HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF FUROSEMIDE [J].
KERREMANS, ALM ;
TAN, Y ;
VANGINNEKEN, CAM ;
GRIBNAU, FWJ .
JOURNAL OF CHROMATOGRAPHY, 1982, 229 (01) :129-139
[8]   PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF THE COMBINATION OF FUROSEMIDE RETARD AND TRIAMTERENE [J].
LOEW, D ;
BARKOW, D ;
SCHUSTER, O ;
KNOELL, HE .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 26 (02) :191-195
[9]   BIOAVAILABILITY OF 2 PREPARATIONS OF FUROSEMIDE AND THEIR PHARMACOLOGICAL ACTIVITY IN NORMAL VOLUNTEERS [J].
OGATA, H ;
ZUGARNI, S ;
EJIMA, A ;
KAWATSU, Y .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 24 (06) :791-796
[10]  
ROBINSON PJ, 1984, BRIT J CLIN PHARMACO, V18, pP268